{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T04:51:14Z","timestamp":1791521474984,"version":"4.3.4"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T00:00:00Z","timestamp":1786752000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","metabolismjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Metabolism"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.metabol.2026.156728","type":"journal-article","created":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:33:39Z","timestamp":1786322019000},"page":"156728","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Apolipoprotein M: A liver-derived lipid-binding protein protects against heart failure with preserved ejection fraction by inhibiting TGF-\u03b2 signaling"],"prefix":"10.1016","volume":"184","author":[{"given":"Hong","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuai","family":"Mei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyang","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiangang","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.metabol.2026.156728_bb0005","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/S0140-6736(23)02756-3","article-title":"Heart failure with preserved ejection fraction: everything the clinician needs to know","volume":"403","author":"Campbell","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.metabol.2026.156728_bb0010","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/j.jacc.2023.03.393","article-title":"ACC expert consensus decision pathway on management of heart failure with preserved ejection fraction: a report of the American College of Cardiology Solution Set Oversight Committee","volume":"81","author":"Kittleson","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.metabol.2026.156728_bb0015","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1016\/j.jacc.2023.01.049","article-title":"Heart failure with preserved ejection fraction: JACC scientific statement","volume":"81","author":"Borlaug","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.metabol.2026.156728_bb0020","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/nrcardio.2017.65","article-title":"Epidemiology of heart failure with preserved ejection fraction","volume":"14","author":"Dunlay","year":"2017","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.metabol.2026.156728_bb0025","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/s41569-024-01046-6","article-title":"Global epidemiology of heart failure","volume":"21","author":"Khan","year":"2024","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.metabol.2026.156728_bb0030","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/s41572-024-00540-y","article-title":"Heart failure with preserved ejection fraction","volume":"10","author":"Hamo","year":"2024","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.metabol.2026.156728_bb0035","first-page":"e895","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.metabol.2026.156728_bb0040","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1016\/j.jacc.2025.08.036","article-title":"Central adiposity or hypertension: which drives heart failure with a preserved ejection fraction?","volume":"86","author":"Packer","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.metabol.2026.156728_bb0045","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1016\/j.jacc.2025.07.052","article-title":"Is type 2 diabetes a modifiable risk factor for the evolution and progression of heart failure with a preserved ejection fraction?","volume":"86","author":"Packer","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.metabol.2026.156728_bb0050","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/j.jacc.2025.06.055","article-title":"The adipokine hypothesis of heart failure with a preserved ejection fraction: a novel framework to explain pathogenesis and guide treatment","volume":"86","author":"Packer","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.metabol.2026.156728_bb0055","doi-asserted-by":"crossref","first-page":"31286","DOI":"10.1074\/jbc.274.44.31286","article-title":"A novel human apolipoprotein (apoM)","volume":"274","author":"Xu","year":"1999","journal-title":"J Biol Chem"},{"key":"10.1016\/j.metabol.2026.156728_bb0060","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.3892\/mmr.2015.3658","article-title":"Apolipoprotein M: research progress, regulation and metabolic functions (review)","volume":"12","author":"Huang","year":"2015","journal-title":"Mol Med Rep"},{"key":"10.1016\/j.metabol.2026.156728_bb0065","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1194\/jlr.M600055-JLR200","article-title":"Isolation and characterization of human apolipoprotein M-containing lipoproteins","volume":"47","author":"Christoffersen","year":"2006","journal-title":"J Lipid Res"},{"key":"10.1016\/j.metabol.2026.156728_bb0070","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1074\/jbc.M704576200","article-title":"Effect of apolipoprotein M on high density lipoprotein metabolism and atherosclerosis in low density lipoprotein receptor knock-out mice","volume":"283","author":"Christoffersen","year":"2008","journal-title":"J Biol Chem"},{"key":"10.1016\/j.metabol.2026.156728_bb0075","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1186\/s12872-019-1263-4","article-title":"Apolipoprotein M and sphingosine-1-phosphate complex alleviates TNF-\u03b1-induced endothelial cell injury and inflammation through PI3K\/AKT signaling pathway","volume":"19","author":"Liu","year":"2019","journal-title":"BMC Cardiovasc Disord"},{"key":"10.1016\/j.metabol.2026.156728_bb0080","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s12944-017-0429-2","article-title":"HDL-associated ApoM is anti-apoptotic by delivering sphingosine 1-phosphate to S1P1 & S1P3 receptors on vascular endothelium","volume":"16","author":"Ruiz","year":"2017","journal-title":"Lipids Health Dis"},{"key":"10.1016\/j.metabol.2026.156728_bb0085","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.atherosclerosis.2011.11.031","article-title":"Apolipoprotein M binds oxidized phospholipids and increases the antioxidant effect of HDL","volume":"221","author":"Els\u00f8e","year":"2012","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.metabol.2026.156728_bb0090","doi-asserted-by":"crossref","first-page":"9613","DOI":"10.1073\/pnas.1103187108","article-title":"Endothelium-protective sphingosine-1-phosphate provided by HDL-associated apolipoprotein M","volume":"108","author":"Christoffersen","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.metabol.2026.156728_bb0095","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1161\/CIRCULATIONAHA.119.045323","article-title":"Reduced apolipoprotein m and adverse outcomes across the spectrum of human heart failure","volume":"141","author":"Chirinos","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.metabol.2026.156728_bb0100","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jacbts.2020.11.011","article-title":"Quantitative proteomic analysis of diabetes mellitus in heart failure with preserved ejection fraction","volume":"6","author":"Hanff","year":"2021","journal-title":"JACC Basic Transl Sci"},{"key":"10.1016\/j.metabol.2026.156728_bb0105","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.jacbts.2022.09.010","article-title":"Apolipoprotein M attenuates anthracycline cardiotoxicity and lysosomal injury","volume":"8","author":"Guo","year":"2023","journal-title":"JACC Basic Transl Sci"},{"key":"10.1016\/j.metabol.2026.156728_bb0110","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aal2722","article-title":"An engineered S1P chaperone attenuates hypertension and ischemic injury","volume":"10","author":"Swendeman","year":"2017","journal-title":"Sci Signal"},{"key":"10.1016\/j.metabol.2026.156728_bb0115","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001779","article-title":"UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age","volume":"12","author":"Sudlow","year":"2015","journal-title":"PLoS Med"},{"key":"10.1016\/j.metabol.2026.156728_bb0120","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1093\/eurheartj\/ehx254","article-title":"UK Biobank: opportunities for cardiovascular research","volume":"40","author":"Littlejohns","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.metabol.2026.156728_bb0125","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1161\/ATVBAHA.124.322367","article-title":"ApoM and major adverse cardiovascular events in chronic kidney disease: a prospective cohort study","volume":"45","author":"Stadler","year":"2025","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.metabol.2026.156728_bb0130","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1038\/s41586-019-1100-z","article-title":"Nitrosative stress drives heart failure with preserved ejection fraction","volume":"568","author":"Schiattarella","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.metabol.2026.156728_bb0135","article-title":"Sphingosine-1-phosphate signaling in cardiovascular diseases","volume":"13","author":"Wang","year":"2023","journal-title":"Biomolecules"},{"key":"10.1016\/j.metabol.2026.156728_bb0140","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1124\/mol.65.3.744","article-title":"SB-505124 is a selective inhibitor of transforming growth factor-beta type I receptors ALK4, ALK5, and ALK7","volume":"65","author":"DaCosta Byfield","year":"2004","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.metabol.2026.156728_bb0145","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1002\/iub.2112","article-title":"Induction of LOX by TGF-\u03b21\/Smad\/AP-1 signaling aggravates rat myocardial fibrosis and heart failure","volume":"71","author":"Lu","year":"2019","journal-title":"IUBMB Life"},{"key":"10.1016\/j.metabol.2026.156728_bb0150","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1194\/jlr.M700103-JLR200","article-title":"Hydrophobic ligand binding properties of the human lipocalin apolipoprotein M","volume":"48","author":"Ahnstr\u00f6m","year":"2007","journal-title":"J Lipid Res"},{"key":"10.1016\/j.metabol.2026.156728_bb0155","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0014-5793(01)02544-3","article-title":"Proposed lipocalin fold for apolipoprotein M based on bioinformatics and site-directed mutagenesis","volume":"499","author":"Duan","year":"2001","journal-title":"FEBS Lett"},{"key":"10.1016\/j.metabol.2026.156728_bb0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlr.2024.100648","article-title":"The adipocyte apolipoprotein M is negatively associated with inflammation","volume":"65","author":"Frances","year":"2024","journal-title":"J Lipid Res"},{"key":"10.1016\/j.metabol.2026.156728_bb0165","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1038\/s41366-024-01510-w","article-title":"Identification of circulating apolipoprotein M as a new determinant of insulin sensitivity and relationship with adiponectin","volume":"48","author":"Frances","year":"2024","journal-title":"Int J Obes (Lond)"},{"key":"10.1016\/j.metabol.2026.156728_bb0170","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/s41392-024-01764-w","article-title":"TGF-\u03b2 signaling in health, disease, and therapeutics","volume":"9","author":"Deng","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.metabol.2026.156728_bb0175","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1080\/14728222.2024.2316735","article-title":"TGF-\u03b2 as a therapeutic target in the infarcted and failing heart: cellular mechanisms, challenges, and opportunities","volume":"28","author":"Frangogiannis","year":"2024","journal-title":"Expert Opin Ther Targets"},{"key":"10.1016\/j.metabol.2026.156728_bb0180","doi-asserted-by":"crossref","first-page":"8531","DOI":"10.7150\/thno.116477","article-title":"FBLN7 KO attenuates age-related cardiac fibrosis by promoting TGFBR3\/ALK1\/Smad1 signaling and inhibiting the profibrotic phenotypes of cardiac fibroblasts","volume":"15","author":"Zheng","year":"2025","journal-title":"Theranostics"},{"key":"10.1016\/j.metabol.2026.156728_bb0185","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1093\/cvr\/cvaa228","article-title":"Heart failure with preserved ejection fraction: insights into diagnosis and pathophysiology","volume":"117","author":"Nagueh","year":"2021","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.metabol.2026.156728_bb0190","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2017.00461","article-title":"Targeting TGF-\u03b2 mediated SMAD signaling for the prevention of fibrosis","volume":"8","author":"Walton","year":"2017","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.metabol.2026.156728_bb0195","doi-asserted-by":"crossref","first-page":"5181","DOI":"10.1096\/fj.201801748R","article-title":"Apolipoprotein M suppresses the phenotypes of IgA nephropathy in hyper-IgA mice","volume":"33","author":"Kurano","year":"2019","journal-title":"FASEB J"},{"key":"10.1016\/j.metabol.2026.156728_bb0200","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.trsl.2023.02.004","article-title":"Apolipoprotein M\/sphingosine 1-phosphate protects against diabetic nephropathy","volume":"258","author":"Kurano","year":"2023","journal-title":"Transl Res"},{"key":"10.1016\/j.metabol.2026.156728_bb0205","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1093\/cvr\/cvaa324","article-title":"Cardiac fibrosis","volume":"117","author":"Frangogiannis","year":"2021","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.metabol.2026.156728_bb0210","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1038\/s41467-025-56796-9","article-title":"Structures of TGF-\u03b2 with betaglycan and signaling receptors reveal mechanisms of complex assembly and signaling","volume":"16","author":"Wieteska","year":"2025","journal-title":"Nat Commun"},{"key":"10.1016\/j.metabol.2026.156728_bb0215","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.atherosclerosis.2018.06.815","article-title":"Apolipoprotein M in patients with chronic kidney disease","volume":"275","author":"S\u00f8rensen","year":"2018","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.metabol.2026.156728_bb0220","doi-asserted-by":"crossref","first-page":"4167","DOI":"10.1111\/bph.14463","article-title":"Successful treatment of established heart failure in mice with recombinant HDL (Milano)","volume":"175","author":"Aboumsallem","year":"2018","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.metabol.2026.156728_bb0225","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19113399","article-title":"Reconstituted HDL (Milano) treatment efficaciously reverses heart failure with preserved ejection fraction in mice","volume":"19","author":"Mishra","year":"2018","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.metabol.2026.156728_bb0230","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20061273","article-title":"Effective treatment of diabetic cardiomyopathy and heart failure with reconstituted HDL (Milano) in mice","volume":"20","author":"Aboumsallem","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.metabol.2026.156728_bb0235","doi-asserted-by":"crossref","first-page":"2801","DOI":"10.1074\/jbc.M113.499913","article-title":"Hepatic apolipoprotein M (apoM) overexpression stimulates formation of larger apoM\/sphingosine 1-phosphate-enriched plasma high density lipoprotein","volume":"289","author":"Liu","year":"2014","journal-title":"J Biol Chem"}],"container-title":["Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049526002416?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049526002416?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T04:42:03Z","timestamp":1791520923000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0026049526002416"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":47,"alternative-id":["S0026049526002416"],"URL":"https:\/\/doi.org\/10.1016\/j.metabol.2026.156728","relation":{},"ISSN":["0026-0495"],"issn-type":[{"value":"0026-0495","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Apolipoprotein M: A liver-derived lipid-binding protein protects against heart failure with preserved ejection fraction by inhibiting TGF-\u03b2 signaling","name":"articletitle","label":"Article Title"},{"value":"Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.metabol.2026.156728","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"156728"}}